Dr. Kenneth Kalunian discusses the Lupus Foundation of America Collective Data Analysis Initiative (LFA CDAI) which is providing insight into the impact various background medications may have on lupus clinical trial outcomes.
Treat-to-Target in Lupus
Treat-to-target is a treatment approach where the physician and the patient agree on specific goals, methods and deadlines for achieving specific outcomes. If the agreed upon treatment strategy does not move toward the goal, the strategy is changed. Treatment goals focus on achieving measurable improvements to the patient’s quality of life.
This concept has been used successfully in other diseases, including rheumatoid arthritis and diabetes. Given its success in improving patients’ health status, a group of lupus experts wanted to determine whether such an approach might be effective in treating lupus.
An international committee, composed of specialists in rheumatology, nephrology, dermatology, internal medicine and clinical immunology, and a patient representative, has been meeting since 2012 and has published a set of principles and recommendations for implementing the treat-to-target concept for managing lupus. Dr. Ronald van Vollenhoven, professor of Clinical Therapy Research at the Karolinska Institute in Stockholm, Sweden, is leading the group.
In this podcast, developed for the Lupus Foundation of America website, lupus.org, Dr. van Vollenhoven describes the concept and its potential benefits in managing lupus, which affects at least five million people worldwide.
Date: July 22, 2014
Presenter: Dr. Ronald van Vollenhoven, professor of Clinical Therapy Research at the Karolinska Institute in Stockholm, Sweden
Dr. Gary Gilkeson of the Medical University of South Carolina discusses his Lupus Foundation of America funded study on the potential use of human mesenchymal stem cells as a therapy for lupus.